



October 4, 2023

Dear Community,

We are writing to inform you that Ionis will soon initiate a clinical trial – called the PrProfile study – to evaluate ION717 in people diagnosed with prion disease. ION717 is an investigational drug designed to lower the amount of prion protein in the brain. The initiation of this clinical trial reflects a significant milestone in the ION717 development program in prion disease.

The PrProfile study is a global, multi-center, early-phase clinical trial designed to examine the safety, tolerability, and pharmacokinetics of ION717 in individuals diagnosed with symptomatic prion disease. Ionis intends to initiate the trial before the end of 2023.

Once the clinical trial has been initiated, additional information, including site locations, will be available on [clinicaltrials.gov](https://clinicaltrials.gov) and will be updated periodically as global study startup activities unfold. We encourage those interested in enrolling to speak with their physician or the staff at a trial site. Ionis is not directly involved in enrollment decisions at clinical trial sites.

The information gained from the PrProfile study will inform next steps in the ION717 development program, which may include additional clinical trials.

We are grateful for our partnership with the prion disease community since the earliest days of our research program. We will continue to provide updates on the program at key milestones.

Sincerely,  
Ionis ION717 Team

Below is additional information you may find helpful:

***Is there a way to receive ION717 outside the clinical trial, such as for people not eligible for this clinical trial and people who don't live near a clinical trial site?***

Evaluation of the safety and efficacy of ION717 in clinical trials is essential to establishing whether ION717 can help people diagnosed with prion disease. For this reason, ION717 is not available outside this clinical trial at this time. We are working diligently to initiate, enroll, and complete the clinical trials necessary to evaluate ION717 in individuals with prion disease.

***When do you expect results from this clinical trial?***

The clinical trial end date will be listed on [clinicaltrials.gov](https://clinicaltrials.gov) when available. Due to the complex nature of clinical development, those timelines could change. We are committed to communicating updates in a timely manner as milestones occur.

***Why are you not including healthy individuals with genetic variants that put them at risk for developing prion disease in this clinical trial, and do you plan to include them in the future?***

The PrProfile clinical trial was designed with input and collaboration from scientists, clinicians, regulators, and the prion disease community. The decision to focus this trial on individuals diagnosed with symptomatic prion disease is based on our belief that this pathway will enable the quickest opportunity to evaluate whether ION717 will help people with prion disease. The information from this study and our additional research will help determine next steps in the program.

***If the studies go well, when do you expect to file for regulatory approval?***

Our current focus is on completing the final steps necessary to initiate the PrProfile study and opening the clinical trial locations. Once the trial has initiated, we will work urgently with the study investigators and the prion disease community to enroll and complete the study as quickly as possible. We will then be in a position to determine next steps in the program. It is premature to predict if or when we will file for regulatory approval.

Individuals and families interested in participating in the PrProfile clinical trial should discuss the trial with their clinical team.

[CJD Foundation](#) (US) and [CJD International Support Alliance](#) are additional community resources that provide education and support to those affected by prion disease.

For more information on Ionis, please visit [www.ionispharma.com](http://www.ionispharma.com) or contact us at [patients@ionisph.com](mailto:patients@ionisph.com).